Clinical Research Directory
Browse clinical research sites, groups, and studies.
AI-PROGNOSIS - Digital Biomarkers Development Study (dBM-DEV)
Sponsor: University Hospital, Toulouse
Summary
dBM-dev study is a multicentre low-intervention research study which concerns REM sleep behaviour disorder (RBD) who is the best predictor for neurodegenerative diseases including Parkinson's disease (PD). RBD can only be confirmed by polysomnography, which is a cumbersome procedure. The main objective of this study is to identify a novel, robust dBM for the detection of RBD using smartwatch-based recordings of passive data.The study is conducted step-wise on two subsequent cohorts referred to as the development cohort and the confirmation cohort.
Official title: AI-based Parkinson's Disease Risk Assessment and Prognosis - Digital Biomarkers Development, Validation and Verification Study (AI-PROGNOSIS dBM-DEV Study)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
90
Start Date
2024-09-20
Completion Date
2025-07-15
Last Updated
2024-08-27
Healthy Volunteers
Yes
Conditions
Interventions
connected smartwatch
The smartwatch is worn by the patient and data are sent automatically to a server that detects if there are signs of RBD.
Locations (4)
Neurology Toulouse Hospital
Toulouse, France
Klinik und Poliklinik für Neurologie of University Hospital (Regulatory autorization pending)
Dresden, Germany
Hospital Ruber Internacional
Madrid, Spain
King's college of London (Regulatory authorization pending)
London, United Kingdom